S. 775
Referred to CommitteeIncreasing Transparency in Generic Drug Applications Act
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
3/14/2023 • Senate
Summary
Increasing Transparency in Generic Drug Applications Act
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Introduced in Senate • 3/14/2023
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (4)
Party Breakdown
Sponsor
Cosponsors (3)
Bill Journey
Originated in the Senate
Introduced
March 14, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Related Bills (5)
H.R. 3561
PATIENT Act of 2023
S. 1114
Expanding Access to Low-Cost Generics Act of 2023
H.R. 3839
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
H.R. 5378
Lower Costs, More Transparency Act
S. 4338
Increasing Transparency in Generic Drug Applications Act